{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:50:29Z","timestamp":1744206629860},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1960,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1093\/annonc\/mdu142","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T00:55:02Z","timestamp":1397350502000},"page":"1391-1397","source":"Crossref","is-referenced-by-count":11,"title":["Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"H.","family":"Gill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.Y.","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.W.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.L.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu142_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu142_bb0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management","volume":"87","author":"Vose","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdu142_bb0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu142_bb0025","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu142_bb0030","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu142_bb0035","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu142_bb0040","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu142_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu142_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdu142_bb0055","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu142_bb0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu142_bb0065","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1182\/blood-2011-05-354530","article-title":"Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study","volume":"118","author":"Au","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu142_bb0070","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1182\/blood-2010-11-283598","article-title":"From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia","volume":"117","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu142_bb0075","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jnci\/91.9.772","article-title":"Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations","volume":"91","author":"Zhu","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu142_bb0080","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00228-002-0514-x","article-title":"Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies","volume":"58","author":"Kumana","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdu142_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.870","article-title":"Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study","volume":"27","author":"Chang","year":"2009","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdu142_bb0090","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu142_bb0095","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","article-title":"French GOELAMS Group. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group","volume":"95","author":"Gressin","year":"2010","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdu142_bb0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdu142_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood-2006-01-0054","article-title":"Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety","volume":"108","author":"Siu","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdu142_bb0110","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu142_bb0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdu142_bb0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-013-1866-2","article-title":"Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1","volume":"93","author":"Lo","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdu142_bb0125","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00277-002-0552-6","article-title":"Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease","volume":"81","author":"Au","year":"2002","journal-title":"Ann Hematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/7\/1391\/24064595\/mdu142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T21:41:43Z","timestamp":1716673303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419366931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0923753419366931"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu142","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}